Stock Events

Stock Events

Decoy Therapeutics 

$2.94
44
-$0.07-2.33% 16:05 Today

Statistics

Day High
3.07
Day Low
2.94
52W High
70.8
52W Low
2.85
Volume
7,687
Avg. Volume
249,801
Mkt Cap
1.93M
P/E Ratio
0.06
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12NovExpected
Q3 2025
Q1 2026
Q2 2026
Next
-403.2
-269.76
-136.32
-2.88
Expected EPS
-3.1224
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-12.52MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.91B
BioMarin Pharmaceutical develops and commercializes innovative therapies for rare genetic diseases, overlapping with Salarius' focus on rare cancers.
CRISPR Therapeutics
CRSP
Mkt Cap5.75B
CRISPR Therapeutics is involved in gene editing, a cutting-edge technology that could address cancer in ways competitive to Salarius' approach.
Novartis
NVS
Mkt Cap301.95B
Novartis offers a broad portfolio of oncology drugs, directly competing with Salarius Pharmaceuticals in the cancer treatment market.
Gilead Sciences
GILD
Mkt Cap181.18B
Gilead Sciences has a strong presence in oncology and cell therapy, areas that Salarius is also targeting.
AMGEN
AMGN
Mkt Cap237.52B
Amgen has a diverse oncology portfolio, including treatments for rare cancers, making it a direct competitor.
Pfizer
PFE
Mkt Cap159.99B
Pfizer has a large and expanding oncology division, competing across a range of cancer treatments, including those for rare cancers.
Merck
MRK
Mkt Cap376.37B
Merck is known for its cancer treatments, including immunotherapies that compete with Salarius' therapeutic approaches.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.87B
Regeneron Pharmaceuticals, with its focus on innovative biologics for cancer treatment, competes in the same biopharmaceutical space as Salarius.

About

Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.
Show more...
CEO
Frederick E. Pierce
Employees
11
Country
United States
ISIN
US79400X6022
WKN
000A424DB

Listings

STU
DE
FP11.STU
MU
DE
FP11.MU
XNAS
US
DCOY
BOATS
BOATS
DCOY.BOATS

0 Comments

Share your thoughts

FAQ

What is Decoy Therapeutics stock price today?▼
The current price of DCOY is $2.94 USD — it has decreased by -2.33% in the past 24 hours. Watch Decoy Therapeutics stock price performance more closely on the chart.
What is Decoy Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Decoy Therapeutics stocks are traded under the ticker DCOY.
What is Decoy Therapeutics market cap?▼
Today Decoy Therapeutics has the market capitalization of 1.93M
When is the next Decoy Therapeutics earnings date?▼
Decoy Therapeutics is going to release the next earnings report on November 12, 2026.
What is Decoy Therapeutics revenue for the last year?▼
Decoy Therapeutics revenue for the last year amounts to 0 USD.
What is Decoy Therapeutics net income for the last year?▼
DCOY net income for the last year is -12.52M USD.
How many employees does Decoy Therapeutics have?▼
As of August 27, 2026, the company has 11 employees.
In which sector is Decoy Therapeutics located?▼
Decoy Therapeutics operates in the Health & Wellness sector.
When did Decoy Therapeutics complete a stock split?▼
The last stock split for Decoy Therapeutics was on March 09, 2026 with a ratio of 1:12.
Where is Decoy Therapeutics headquartered?▼
Decoy Therapeutics is headquartered in HOUSTON, United States.